<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01266642</url>
  </required_header>
  <id_info>
    <org_study_id>2010-0559</org_study_id>
    <secondary_id>NCI-2011-00253</secondary_id>
    <secondary_id>2010-0559</secondary_id>
    <nct_id>NCT01266642</nct_id>
  </id_info>
  <brief_title>Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer</brief_title>
  <official_title>Randomized Trial of Hypofractionated Whole Breast Irradiation Versus Conventionally Fractionated Whole Breast Irradiation for Ductal Carcinoma In Situ and Early Invasive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies how well hypofractionated radiation therapy (RT) works&#xD;
      compared to standard RT in treating patients with ductal breast carcinoma in situ (DCIS) or&#xD;
      early invasive breast cancer. Radiation therapy (RT) uses high energy x-rays to kill tumor&#xD;
      cells. Giving higher doses of RT over a shorter period of time may kill more tumor cells and&#xD;
      have fewer side effects. It is not yet known if hypofractionated RT is more effective than&#xD;
      standard RT in treating breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To compare patient-reported cosmetic outcome at 3 years using the Breast Cancer Treatment&#xD;
      Outcomes Scale (BCTOS) for patients assigned to hypofractionated whole breast irradiation&#xD;
      (HF-WBI) versus conventionally fractionated whole breast irradiation (CF-WBI).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine patient-reported cosmetic outcome using the BCTOS at 6 months, 1, 2, 4, and 5&#xD;
      years.&#xD;
&#xD;
      II. To determine physician-rated cosmetic outcome at 6 months, 1, 2, 3, 4, and 5 years using&#xD;
      the Radiation Therapy and Oncology Group (RTOG) scale for physician assessment.&#xD;
&#xD;
      III. To determine the level of agreement between patient-rated cosmetic outcome and&#xD;
      physician-rated cosmetic outcome at the various time points assessed.&#xD;
&#xD;
      IV. To determine the 5-year and risk of pathologically-confirmed invasive and/or in situ&#xD;
      ipsilateral breast tumor recurrence (IBTR) for patients with ductal carcinoma in situ (DCIS)&#xD;
      and early invasive breast cancer.&#xD;
&#xD;
      V. To determine patient-reported functional status and breast pain using the BCTOS at 6&#xD;
      months, 1, 2, 3, 4, and 5 years after treatment.&#xD;
&#xD;
      VI. To determine maximal acute (within 6 weeks of treatment) and late (more than 6 weeks&#xD;
      after treatment) skin and soft tissue toxicities using the National Cancer Institute (NCI)&#xD;
      Common Terminology Criteria for Adverse Events (CTCAE) version (v)4.0 scale.&#xD;
&#xD;
      VII. To determine the relationship between the volume of breast tissue receiving excessive&#xD;
      dose (defined as greater than 105% of the prescription dose) and the risk of adverse&#xD;
      cosmesis.&#xD;
&#xD;
      VIII. To determine the relationship between bra cup size and the risk of adverse cosmesis.&#xD;
&#xD;
      IX. To determine whether there is a statistical interaction between breast volume and volume&#xD;
      of tissue receiving greater than 105% of the prescription dose in predicting adverse&#xD;
      cosmesis.&#xD;
&#xD;
      X. To determine in an exploratory analysis whether any other demographic, clinical, and&#xD;
      pathologic factors correlate with risk of adverse cosmesis, quality of life, body image,&#xD;
      image investment, and risk of IBTR.&#xD;
&#xD;
      XI. To determine if the C-509T variant allele of transforming growth factor-beta (TGF-beta)&#xD;
      is associated with an increased risk of grade 2 or higher fibrosis (as determined by the&#xD;
      Subjective, Objective, Medical Management, Analytic [SOMA] scale) three years after&#xD;
      completion of radiation.&#xD;
&#xD;
      XII. To compare the cost of radiation for patients treated on the two treatment arms.&#xD;
&#xD;
      XIII. To compare patient quality of life, body image, and appearance investment for the two&#xD;
      treatment arms using the Functional Assessment of Cancer Therapy-Breast (FACT-B), Appearance&#xD;
      Schemas Inventory-Revised (ASI-R), and Body Image Scale, respectively.&#xD;
&#xD;
      XIV. To contribute additional blood samples to protocol LAB02-086 which is a case-control&#xD;
      study investigating deoxyribonucleic acid (DNA) repair phenotypes and genotypes in breast&#xD;
      cancer.&#xD;
&#xD;
      XV. To assess the psychometric profile of the Functional Assessment of Cancer Therapy-Breast&#xD;
      (FACT-B) version 4 in collaboration with investigators from the Department of Medical Social&#xD;
      Science, Northwestern University Feinberg School of Medicine.&#xD;
&#xD;
      XVI. To determine the influence of oncoplastic lumpectomy on the following outcomes:&#xD;
      physician- and patient-reported cosmetic outcomes, other patient-reported health-related&#xD;
      quality of life outcomes, and photographic measurements of breast cosmetic outcome.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
      ARM I: Patients undergo HF-WBI comprising external beam RT 5 days a week for approximately 3&#xD;
      weeks.&#xD;
&#xD;
      ARM II: Patients undergo CF-WBI comprising external beam RT 5 days a week for approximately 5&#xD;
      weeks.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 6 months and then annually&#xD;
      for 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 8, 2011</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Actual">November 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Scores of Either &lt;2.5 or &gt;=2.5 on the Breast Cancer Treatment Outcome Scale (BCTOS) Cosmesis</measure>
    <time_frame>3 years after completing radiation therapy</time_frame>
    <description>BCTOS cosmesis score range from 1 to 4, and scores of 2.5 or more indicate adverse cosmetic outcomes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Panel Physicians Rated Cosmesis</measure>
    <time_frame>3 years after completing radiation therapy.</time_frame>
    <description>A group of three attending physicians blinded to the treatment scored the photographs using the Radiation Therapy and Oncology Group (RTOG) criteria. RTOG scale range from 1 (excellent), 2 (good), 3 (fair), and 4 (poor).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">301</enrollment>
  <condition>Ductal Breast Carcinoma In Situ</condition>
  <condition>Invasive Breast Carcinoma</condition>
  <condition>Stage I Breast Cancer AJCC v6</condition>
  <condition>Stage IA Breast Cancer AJCC v7</condition>
  <condition>Stage IB Breast Cancer AJCC v7</condition>
  <condition>Stage II Breast Cancer AJCC v6 and v7</condition>
  <condition>Stage IIA Breast Cancer AJCC v6 and v7</condition>
  <condition>Stage IIB Breast Cancer AJCC v6 and v7</condition>
  <arm_group>
    <arm_group_label>Arm I (HF-WBI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo HF-WBI comprising external beam RT 5 days a week for approximately 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (CF-WBI)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo CF-WBI comprising external beam RT 5 days a week for approximately 5 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>External Beam Radiation Therapy</intervention_name>
    <description>Undergo HF-WBI</description>
    <arm_group_label>Arm I (HF-WBI)</arm_group_label>
    <other_name>Definitive Radiation Therapy</other_name>
    <other_name>EBRT</other_name>
    <other_name>External Beam Radiation</other_name>
    <other_name>External Beam Radiotherapy</other_name>
    <other_name>External Beam RT</other_name>
    <other_name>external radiation</other_name>
    <other_name>External Radiation Therapy</other_name>
    <other_name>external-beam radiation</other_name>
    <other_name>Radiation, External Beam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>External Beam Radiation Therapy</intervention_name>
    <description>Undergo CF-WBI</description>
    <arm_group_label>Arm II (CF-WBI)</arm_group_label>
    <other_name>Definitive Radiation Therapy</other_name>
    <other_name>EBRT</other_name>
    <other_name>External Beam Radiation</other_name>
    <other_name>External Beam Radiotherapy</other_name>
    <other_name>External Beam RT</other_name>
    <other_name>external radiation</other_name>
    <other_name>External Radiation Therapy</other_name>
    <other_name>external-beam radiation</other_name>
    <other_name>Radiation, External Beam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionated Radiation Therapy</intervention_name>
    <description>Undergo HF-WBI</description>
    <arm_group_label>Arm I (HF-WBI)</arm_group_label>
    <other_name>Hypofractionated Radiotherapy</other_name>
    <other_name>hypofractionation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Optional correlative studies</description>
    <arm_group_label>Arm I (HF-WBI)</arm_group_label>
    <arm_group_label>Arm II (CF-WBI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (HF-WBI)</arm_group_label>
    <arm_group_label>Arm II (CF-WBI)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (HF-WBI)</arm_group_label>
    <arm_group_label>Arm II (CF-WBI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Whole Breast Irradiation</intervention_name>
    <description>Undergo HF-WBI</description>
    <arm_group_label>Arm I (HF-WBI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Whole Breast Irradiation</intervention_name>
    <description>Undergo CF-WBI</description>
    <arm_group_label>Arm II (CF-WBI)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically confirmed ductal carcinoma in situ of the breast or early invasive&#xD;
             breast cancer defined as pathologic stage Tis, T1, or T2, N0, N1mic, or N1a&#xD;
             (pathologic staging of the axilla is required for all patients with invasive disease&#xD;
             but is not required for patients with ductal carcinoma in situ [DCIS] only); (upfront&#xD;
             pathologic stage cannot be assigned to patients treated with neoadjuvant chemotherapy;&#xD;
             for such patients, the criteria for pathologic stage shall be applied to the initial&#xD;
             clinical stage)&#xD;
&#xD;
          -  Treatment with breast conserving surgery&#xD;
&#xD;
          -  Final surgical margins must be negative, defined as no evidence for ductal carcinoma&#xD;
             in situ or invasive breast cancer touching the inked surgical margin; if the invasive&#xD;
             or in situ breast cancer approaches within less than 1 mm of the final surgical&#xD;
             margin, then a reexcision is strongly encouraged; lobular carcinoma in situ at the&#xD;
             final surgical margin will be disregarded&#xD;
&#xD;
          -  Attending radiation oncologist declares intention to treat the whole breast only and&#xD;
             that a third radiation field to treat regional lymph nodes is not planned (radiation&#xD;
             of the undissected level I/II axilla with high tangents is allowed)&#xD;
&#xD;
          -  If the patient has a history of a prior non-breast cancer, all treatment for this&#xD;
             cancer must have been completed prior to study registration and the patient must have&#xD;
             no evidence of disease for this prior non-breast cancer&#xD;
&#xD;
          -  Patients must be enrolled on the trial within 12 weeks of the later of two dates: the&#xD;
             final breast conserving surgical procedure or administration of the last cycle of&#xD;
             concurrent cytotoxic chemotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pathologic or clinical evidence for a stage T3 or T4 breast cancer&#xD;
&#xD;
          -  Pathologic evidence for involvement of 4 or more axillary lymph nodes, or imaging&#xD;
             evidence of involvement of infraclavicular, supraclavicular, or internal mammary lymph&#xD;
             nodes&#xD;
&#xD;
          -  Clinical or pathologic evidence for distant metastases&#xD;
&#xD;
          -  Any prior diagnosis of invasive or ductal carcinoma in situ breast cancer in either&#xD;
             breast&#xD;
&#xD;
          -  Current diagnosis of bilateral breast cancer&#xD;
&#xD;
          -  History of therapeutic irradiation to the breast, lower neck, mediastinum or other&#xD;
             area in which there could potentially be overlap with the affected breast&#xD;
&#xD;
          -  Patients not fluent in English or Spanish (The BCTOS will be available in these two&#xD;
             languages)&#xD;
&#xD;
          -  Patient is pregnant&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin D Smith</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UF Cancer Center at Orlando Health</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson in The Woodlands</name>
      <address>
        <city>Conroe</city>
        <state>Texas</state>
        <zip>77384</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson West Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77079</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson League City</name>
      <address>
        <city>League City</city>
        <state>Texas</state>
        <zip>77573</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson in Sugar Land</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 20, 2010</study_first_submitted>
  <study_first_submitted_qc>December 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2010</study_first_posted>
  <results_first_submitted>September 21, 2021</results_first_submitted>
  <results_first_submitted_qc>October 21, 2021</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 19, 2021</results_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Carcinoma, Ductal, Breast</mesh_term>
    <mesh_term>Breast Carcinoma In Situ</mesh_term>
    <mesh_term>Carcinoma, Intraductal, Noninfiltrating</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 16, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT01266642/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from provider clinics at 3 academic medical centers between February 2011 and February 2014. Women with stage 0 to II breast cancer were randomly assigned to CF-WBI or HF-WBI, stratified by chemotherapy, margin status, cosmesis, and breast size.</recruitment_details>
      <pre_assignment_details>Of the 301 participants enrolled, 287 were fully eligible and were randomized to protocol, 13 were excluded (8) Insurance would not cover protocol therapy, (4) withdrew consent and (1) became ineligible due to finding of other primary cancer on simulation CT. 1 participant was registered twice.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CF-WBI</title>
          <description>50 Gy in 25 fractions to the whole breast, plus a tumor bed boost of 10Gy in 5 fractions or of 14Gy in 7 fractions (dependent on surgical margins).</description>
        </group>
        <group group_id="P2">
          <title>HF-WBI</title>
          <description>42.56 Gy in 16 fractions to the whole breast, plus tumor bed boost of 10Gy in 4 fractions or 12.5Gy in 5 fractions (dependent on surgical margins).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="149"/>
                <participants group_id="P2" count="138"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="149"/>
                <participants group_id="P2" count="137"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CF-WBI</title>
          <description>50 Gy in 25 fractions to the whole breast, plus a tumor bed boost of 10Gy in 5 fractions or of 14Gy in 7 fractions (dependent on surgical margins).</description>
        </group>
        <group group_id="B2">
          <title>HF-WBI</title>
          <description>42.56 Gy in 16 fractions to the whole breast, plus tumor bed boost of 10Gy in 4 fractions or 12.5Gy in 5 fractions (dependent on surgical margins).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="149"/>
            <count group_id="B2" value="138"/>
            <count group_id="B3" value="287"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.3" spread="8"/>
                    <measurement group_id="B2" value="60" spread="8.6"/>
                    <measurement group_id="B3" value="60.2" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                    <measurement group_id="B2" value="138"/>
                    <measurement group_id="B3" value="287"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="118"/>
                    <measurement group_id="B3" value="251"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="249"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                    <measurement group_id="B2" value="138"/>
                    <measurement group_id="B3" value="287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Scores of Either &lt;2.5 or &gt;=2.5 on the Breast Cancer Treatment Outcome Scale (BCTOS) Cosmesis</title>
        <description>BCTOS cosmesis score range from 1 to 4, and scores of 2.5 or more indicate adverse cosmetic outcomes.</description>
        <time_frame>3 years after completing radiation therapy</time_frame>
        <population>Intent to treat population (all participants assigned to CF-WBI or HF-WBI).</population>
        <group_list>
          <group group_id="O1">
            <title>CF-WBI</title>
            <description>50 Gy in 25 fractions to the whole breast, plus a tumor bed boost of 10Gy in 5 fractions or of 14Gy in 7 fractions (dependent on surgical margins).</description>
          </group>
          <group group_id="O2">
            <title>HF-WBI</title>
            <description>42.56 Gy in 16 fractions to the whole breast, plus tumor bed boost of 10Gy in 4 fractions or 12.5Gy in 5 fractions (dependent on surgical margins).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Scores of Either &lt;2.5 or &gt;=2.5 on the Breast Cancer Treatment Outcome Scale (BCTOS) Cosmesis</title>
          <description>BCTOS cosmesis score range from 1 to 4, and scores of 2.5 or more indicate adverse cosmetic outcomes.</description>
          <population>Intent to treat population (all participants assigned to CF-WBI or HF-WBI).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BCTOS cosmesis &lt; 2.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCTOS cosmesis &gt;= 2.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Panel Physicians Rated Cosmesis</title>
        <description>A group of three attending physicians blinded to the treatment scored the photographs using the Radiation Therapy and Oncology Group (RTOG) criteria. RTOG scale range from 1 (excellent), 2 (good), 3 (fair), and 4 (poor).</description>
        <time_frame>3 years after completing radiation therapy.</time_frame>
        <population>Intent to treat population (all participants assigned to CF-WBI or HF-WBI).</population>
        <group_list>
          <group group_id="O1">
            <title>CF-WBI</title>
            <description>50 Gy in 25 fractions to the whole breast, plus a tumor bed boost of 10Gy in 5 fractions or of 14Gy in 7 fractions (dependent on surgical margins).</description>
          </group>
          <group group_id="O2">
            <title>HF-WBI</title>
            <description>42.56 Gy in 16 fractions to the whole breast, plus tumor bed boost of 10Gy in 4 fractions or 12.5Gy in 5 fractions (dependent on surgical margins).</description>
          </group>
        </group_list>
        <measure>
          <title>Panel Physicians Rated Cosmesis</title>
          <description>A group of three attending physicians blinded to the treatment scored the photographs using the Radiation Therapy and Oncology Group (RTOG) criteria. RTOG scale range from 1 (excellent), 2 (good), 3 (fair), and 4 (poor).</description>
          <population>Intent to treat population (all participants assigned to CF-WBI or HF-WBI).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Excellent/Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fair/Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the time radiotherapy was completed until 5-years post treatment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>CF-WBI</title>
          <description>50 Gy in 25 fractions to the whole breast, plus a tumor bed boost of 10Gy in 5 fractions or of 14Gy in 7 fractions (dependent on surgical margins).</description>
        </group>
        <group group_id="E2">
          <title>HF-WBI</title>
          <description>42.56 Gy in 16 fractions to the whole breast, plus tumor bed boost of 10Gy in 4 fractions or 12.5Gy in 5 fractions (dependent on surgical margins).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="149" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="138" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="135" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="114" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Superficial soft tissue fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>Fibrosis deep connective tissue</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" subjects_affected="123" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>Breast atrophy</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="96" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>Nipple deformity</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="132" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="109" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>Skin induration</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="148" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="130" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>Telangiectasia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="120" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphedema</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Benjamin Smith, Professor, Radiation Oncology Department</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>(713) 563-2380</phone>
      <email>bsmith3@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

